Favorite Abstracts from the 2019 ACR Annual Meeting

Our next journal club will be Thursday, December 12th at 9pm Eastern Time / 8pm Central Time (click here to find this in your local time zone).

We’ll be discussing our favorite abstracts from the ACR 2019 Annual Meeting, chosen by the #RheumJC team. Feel free to let us know what your favorite abstracts during the session.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Treatment Delays Associated with Prior Authorization

UPDATED DATE & TIME

Our next journal club will be Wednesday, October 23rd at 8:30pm Eastern Time / 7:30pm Central Time (click here to find this in your local time zone).

We’ll be discussing the recently published Arthritis Care & Research article: Treatment Delays Associated with Prior Authorization for Infusible Medications: A Cohort Study by Dr. Zachary S. Wallace, et al.

The primary author, Dr. Wallace (@zach_wallace_md), will be joining us for the journal club session, so you won’t want to miss this one.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Gene expression biomarkers to predict response to methotrexate

Our next #RheumJC will be Thursday, June 27th at 9pm Eastern Time / 8pm Central Time (click here to find this in your local time zone).

We’ll be discussing the Open Access Arthritis & Rheumatology article: Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Nintedanib for Systemic Sclerosis–Associated ILD

Our next #RheumJC will be Thursday, May 30th at 9pm Eastern Time / 8pm Central Time (click here to find this in your local time zone).

We’ll be discussing the NEJM article: Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Assessing RA Disease Activity using Digital Technology

Our next #RheumJC will be Thursday, April 25th at 9pm Eastern Time / 8pm Central Time (click here to find this in your local time zone).

We’ll be discussing the Arthritis Care & Research article: Assessing RA Disease Activity with PROMIS Measures using Digital Technology.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Tramadol and Mortality in Osteoarthritis

Our next #RheumJC will be Thursday, March 28th at 9pm Eastern Time / 8pm Central Time (click here to find this in your local time zone).

We’ll be discussing the JAMA article: Association of Tramadol With All-Cause Mortality Among Patients With Osteoarthritis

For some bonus learning, we suggest reading the writeup on the Nephmadness 2019: Pain Region, which includes sections on tramadol as well as opioids, NSAIDs, and GABAnergics.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Ustekinumab in Axial Spondyloarthritis

❄️ Happy February! ☃️

Our next #RheumJC will be Thursday, February 28th at 10pm Eastern Time / 9pm Central Time (click here to find this in your local time zone).

We’ll be discussing the Arthritis & Rheumatology article: Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Ustekinumab for Lupus

Happy New Year!

Our first #RheumJC of 2019 will be Thursday, January 31st at 10pm Eastern Time / 9pm Central Time (click here to find this in your local time zone).

We’ll be discussing the Lancet article: Efficacy and safety of ustekinumab, an IL–12 and IL–23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Favorite Abstracts from #ACR18

The next #RheumJC session will be Thursday, November 15th at 10pm Eastern Time / 9pm Central Time (click here to find this in your local time zone).

We’ll be discussing four of our favorite abstracts from the ACR 2018 Annual Meeting, chosen by a combination of the #RheumJC team and your responses to our poll.

To cast your vote in our poll, click on this link (poll ends Wed Nov 14): https://twitter.com/RheumJC/status/1061722574533595137

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Biologic Refractory RA

The next #RheumJC session will be Thursday, September 27th at 10pm Eastern Time / 9pm Central Time (click here to find this in your local time zone).

Based on this months (extremely close) poll, we’ll be doing the ARD BMJ article Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. This article is open access.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.